CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.

Employees - 15, CEO - John J. Alam, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -12.42, Piotroski Score(max is 10): 2, Working Capital: $10615715, Total Assets: $15112918, Retained Earnings: $-105662009, EBIT: -30036491, Total Liabilities: $4497203, Revenue: $322569

AryaFin Target Price - $0.91 - Current Price $ - Analyst Target Price $